New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
06:18 EDTEXELPiper says time to buy shares of Exelixis
Piper Jaffray believes it's time to buy shares of Exelixis with the stock down 56% from the close on March 25. Piper thinks shares at current levels have "washed out" cabozantinib in castration-resistant prostate cancer. It reiterates an Overweight rating on Exelixis with an $11 price target.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:26 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXELExelixis' cobimetinib granted first regulatory approval in Switzerland
Subscribe for More Information
August 24, 2015
08:32 EDTEXELExelixis granted FDA Breakthrough Therapy Designation for cabozantinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use